| Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. | |
| | |
MedLine Citation:
|
PMID: 22172728 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: The Irbesartan Diabetic Nephropathy Trial (IDNT) demonstrated that irbesartan significantly slowed established Type 2 diabetic nephropathy progression. Estimated glomerular filtration rate (eGFR), now widely used to monitor chronic kidney disease (CKD) progression, was not previously examined in IDNT. This post hoc analysis aimed to confirm IDNT results using eGFR as principal outcome measure.METHODS: Mean change in eGFR from baseline (▵eGFR) was analysed using linear mixed-effects models over time and analysis of covariance at end of study on an intention-to-treat basis. Potential treatment response moderators and/or mediators assessed were CKD stage, blood pressure (BP) and proteinuria.RESULTS: Irbesartan significantly slowed the rate of ΔeGFR decline from 6 to 21 months (P = 0.0048) and 24 to 48 months (P < 0.0001) versus amlodipine and placebo, despite a faster decline in the first month. The longer patients remained on irbesartan the greater the benefit (model-derived estimates for 6-21 and 24-48 month periods were -0.3354 and -0.1947 mL/min/1.73m(2)/month, respectively). Irbesartan slowed the rate of ΔeGFR decline irrespective of baseline CKD stage, BP or proteinuria level. Irbesartan produced rapid and sustained proteinuria reductions, which only partially mediated treatment response. Irbesartan increased serum potassium, but levels stabilized from 6 to 48 months.CONCLUSIONS: In patients with established Type 2 diabetic nephropathy and CKD Stages 1-5, irbesartan safely and significantly slowed the rate of ΔeGFR decline (-2.34 mL/min/1.73m(2)/year) compared to amlodipine (-3.76 mL/min/1.73m(2)/year) and placebo (-3.52 mL/min/1.73m(2)/year). This rate of decline was slower with longer duration of irbesartan treatment and only partly explained by observed reductions in BP and proteinuria. |
| | |
Authors:
|
Marc Evans; Stephen C Bain; Simon Hogan; Rudy W Bilous; |
Related Documents
:
|
21216618 - Obesity and nutrient sensing tor pathway in flies and vertebrates: functional conservat... 10837698 - Intranasal insulin delivery and therapy. 21484408 - 17β-estradiol and vitamin e modulates oxidative stress-induced kidney toxicity in diab... 400128 - Diabetic glucose control: matching plasma insulin concentration to dietary and stress h... 20556538 - Nonalcoholic fatty liver disease associated with obstructive sleep apnea: just a coinci... 21357278 - Intensive blood pressure control affects cerebral blood flow in type 2 diabetes mellitu... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-12-15 |
Journal Detail:
|
Title: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association Volume: - ISSN: 1460-2385 ISO Abbreviation: - Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-12-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8706402 Medline TA: Nephrol Dial Transplant Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
1University Hospital Llandough, Cardiff, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Physical activity and energy expenditure in haemodialysis patients: an international survey.
Next Document: Domain wall motion in perpendicular anisotropy nanowires with edge roughness.